Cantargia: CANFOUR Study On Track, U.S. Trial Preparations
On 23 August, Cantargia AB (ST:CANTA) announced fresh preclinical in vivo data on CAN04 in bladder cancer, which suggests an opportunity to explore this indication....
Symbol | Exchange | Currency |
|---|
On 23 August, Cantargia AB (ST:CANTA) announced fresh preclinical in vivo data on CAN04 in bladder cancer, which suggests an opportunity to explore this indication....
Cantargia AB (ST:CANTA) presented full data (n=22) from the Phase I part of the CANFOUR study at ASCO on 2 June 2019. These data (safety, biomarker and early efficacy data) were...
On 20 October 2018, Cantargia (ST:CANTA) presented interim data from part I of its Phase I/IIa CANFOUR trial with nidanilimab (IL1RAP antibody) at the ESMO congress in Munich,...
Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.
| Average | 17.25 (+165.38% Upside) |
| High | 26.00 |
| Low | 13.00 |
| Price | 6.50 |
| No. of Analysts | 4 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Neutral | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Buy | Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 192.22 | 199.31 | 188.65 | +1.07 | +0.56% | 143.66M | NASDAQ | |||
| 158.93 | 161.55 | 157.68 | +1.10 | +0.70% | 67.36M | NASDAQ | |||
| 59.92 | 60.39 | 59.72 | -0.13 | -0.22% | 15.47M | NYSE | |||
| 204.28 | 207.88 | 202.15 | +4.47 | +2.24% | 27.20M | NASDAQ | |||
| 105.60 | 106.30 | 104.46 | +2.23 | +2.16% | 40.63M | NASDAQ | |||
| 277.66 | 281.06 | 275.20 | +5.37 | +1.97% | 36.44M | NASDAQ | |||
| 40.18 | 40.50 | 40.00 | +0.17 | +0.42% | 16.95M | NYSE | |||
| 100.28 | 102.43 | 98.67 | +2.70 | +2.77% | 83.99M | NASDAQ | |||
| 98.71 | 101.06 | 97.62 | +0.01 | +0.01% | 57.45M | NASDAQ | |||
| 159.98 | 165.85 | 158.50 | -3.23 | -1.98% | 2.42M | NASDAQ | |||
| 271.91 | 274.99 | 266.90 | +7.23 | +2.73% | 56.31M | NASDAQ | |||
| 8.33 | 8.56 | 8.16 | +0.12 | +1.46% | 22.60M | NYSE | |||
| 106.26 | 107.10 | 105.41 | +2.04 | +1.96% | 31.36M | NASDAQ | |||
| 45.79 | 46.94 | 45.12 | +0.83 | +1.85% | 15.33M | NYSE | |||
| 49.73 | 50.25 | 49.40 | +0.27 | +0.55% | 17.77M | NASDAQ |